Stem Cell Clinic

Stem Cell Therapy for Osteoarthritis and Sports Injuries: A Case Study – Video

08-02-2012 11:12 Stem Cell Treatment of Pro/Am dancer and orthodontist, Dr. Janet Vaughan. In attempt to get her dancing career back on track, Dr. Vaughan decided to undergo stem cell therapy at the Stem Cell Institute in Panama City, Panama. Dr. Jorge Paz, Medical Director at the Stem Cell Institute presents Dr. Vaughan's case discussing her injuries and subsequent recovery. After being unable to compete for 2 years, Dr. Vaughan is once again slated to compete on the professional dance circuit with her current professional partner, Mr. Eddie Stutts (Professional 10-Dance World Champion). From 2007-2009, Dr. Vaughan partnered with World Champion Tony Dovolani and competed extensively in the US, winning a National Reserve Pro/Am Rhythm title. Tony Dovolani is best known for his appearances on ABC's hit reality series, "Dancing with the Stars", and has teamed up with Chynna Phillips, Wendy Williams, Audrina Partridge, Kate Gosselin, Kathy Ireland, Susan Lucci, Jane Seymour and other celebrities on the show.

More here:
Stem Cell Therapy for Osteoarthritis and Sports Injuries: A Case Study - Video

(Captioned) Hearing Loss Research : CBR Exclusive! Stem Cells Explored as Cure for Hearing Loss – Video

19-09-2011 13:52 Learn more at http://www.cordblood.com Learn how newborn stem cells are being researched as treatment for patients with hearing loss. An innovative study held at Children's Memorial Hermann Hospital in Houston will be evaluating the effects of a child's own cord blood as treatment for acquired hearing loss. Only CBR offers your family exclusive access to several groundbreaking clinical trials such as this one. CBR was chosen as the only bank to provide cord blood because these studies require consistent processing and storage methods to reduce any possible variables. To learn more about this study, please visit clinicaltrials.gov To learn more about the lifesaving potential of cord blood, order your free information kit here http://www.cordblood.com Disclaimer: Ultimate use of cord blood stem cells will be determined by the treating physician who will consider if they are applicable for the condition and should come from the patient or a suitable donor (like an HLA matched sibling). There is no guarantee that treatments being studied in the laboratory or in clinical trials will be available in the future. CBR is the preferred choice of OB/Gyns. Source: blind survey, GfK Market Measures, 04/07, funded by CBR. © 2011 Cord Blood Registry. All rights reserved. Privacy Policy

Read this article:
(Captioned) Hearing Loss Research : CBR Exclusive! Stem Cells Explored as Cure for Hearing Loss - Video

IntelliCell Demonstrates at the American Sports Medicine Institute Held in Conjunction with and at the Andrews Sports …

NEW YORK--(BUSINESS WIRE)--

IntelliCell BioSciences, Inc. (OTCQB: SVFC.PK) (PINKSHEETS: SVFC.PK); (“IntelliCell”) or the (“Company”), was invited to demonstrate its stromal vascular fraction technology at the recent Baseball Injuries Symposium at the Andrews Sports Medicine Institute in Alabama held and sponsored by USA Baseball. The course Chairman is Dr. James Andrews, and moderated by PT Kevin Wilk, and Dr. Jeff Dugas. One of the courses presented during the three day event was on stem cell technology presented by Dr. Joshua Hackel. Dr. Hackel presented the state of regenerative medicine technology in the role of treating sports injuries. The link is http://www.mediafire.com/?u7bfa662e3r1sdp.

Dr. Hackel compared the IntelliCell SVF technology to several other methods of regenerative medicine being considered to be used by the leading orthopedic sports medicine doctors. Dr. Steven Victor, CEO of IntelliCell stated, "We are extremely excited that IntelliCell’s technology compares very favorably to all the other technologies, for procedures common to all major sports industries. We are extremely grateful to have the opportunity to present to over 200 leading doctors and trainers looking to treat major league, collegiate and amateur baseball players with regenerative medicine. IntelliCell Biosciences believes that its technology will be utilized by such experts this year."

About IntelliCell BioSciences, Inc.

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients. The company is also setting up Centers of Excellence where doctors can treat their patients. In addition, IntelliCell BioSciences is exploring storing the stromal vascular fraction in cryo-storage for future uses. The company is also starting FDA IND clinical trials at major medical centers for clinical indication approval. IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities.

The rest is here:
IntelliCell Demonstrates at the American Sports Medicine Institute Held in Conjunction with and at the Andrews Sports ...

American CryoStem Completes Cell Processing for Clinical Study

RED BANK, NJ--(Marketwire -02/07/12)- American CryoStem Corporation (OTCQB: CRYO.OB - News) announced today that it has completed providing stem cell processing services for Personal Cell Sciences Corp., a cutting edge manufacturer of anti-aging skin care products.

The study involves researching the regenerative function of a conditioned medium obtained from each participant's adipose (fat tissue) derived mesenchymal stem cells and their ability to promote the production or secretion of collagen, elastin and fibronectin related to skin wound healing.

John Arnone, CEO of American CryoStem and Founder of Personal Cell Sciences, commented, "CRYO's patented tissue culture media and its proprietary, aseptic adipose tissue processing methodology allows, as an added benefit for PCS customers to store a clinical grade sample of their own stem cells for future use in regenerative medicine. We are pleased to provide comprehensive Bio-Insurance storage solutions at our clinical facility."

The adipose tissue samples were acquired utilizing a mini-liposuction procedure. A total of sixty milliliters (approximately 2 fluid ounces) of adipose tissue was collected in the physician's office and sent to CRYO's laboratory for processing. Once processed, the resulting stromal vascular fraction (SVF) was forwarded to the Personal Cell Sciences laboratory for proprietary formulation for patient specific products.

"We are very excited to announce our service agreement and participation in this clinical study for Personal Cell Sciences. This contractual manufacturing agreement reinforces our capabilities to provide CRYO's exceptional clinical processing for relevant adult stem cell related products," said Anthony Dudzinski, COO of American CryoStem. "We look forward to our continued business relationship with PCS and expanding these services to other developers to speed their product's time to market."

About American CryoStem: American CryoStem Corporation (OTCQB: CRYO.OB - News) markets clinical processing products and services for Adipose (fat) Tissue and Adipose Derived Adult Stem Cells. CRYO's clinical processing and preservation platform supports the science and applications being discovered globally by providing the highest quality, clinically processed cells and assuring their sterility, viability and growth cap abilities, while at the same time developing cutting edge application, therapies and laboratory products and services for consumers and physicians.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

View original post here:
American CryoStem Completes Cell Processing for Clinical Study

Cryo-Cell International, Inc. Announces Material Transfer Agreement with Stanford University

Oldsmar, Fla (PRWEB) February 07, 2012

Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) and Stanford University announced signing a material transfer agreement to test the efficacy of mesenchymal-like stem cells derived from menstrual blood (MenSCs) in a model of pancreatic islet transplantation for type 1 diabetes treatment. Specifically, the menstrual blood stem cells provided by Cryo-Cell will be tested in vitro and in vivo to enhance pancreatic islet viability, regeneration, and function during the peritransplantation period.

Dr. Magali J Fontaine MD PhD., the principal investigator, stated “We are looking forward to this collaborative effort to contribute to the field of Type I Diabetes research”. Dr. Fontaine is an Assistant Professor of Pathology at Stanford Medical School. Dr. Fontaine is a highly trained basic scientist and pathologist specializing in Transfusion Medicine with a strong interest in cellular therapy.

Dr. Julie G. Allickson, PhD., the co-investigator, added “We are very pleased to partner with Dr. Fontaine to explore further functional capabilities of menstrual blood stem cells in a model for Type I Diabetes. We have demonstrated that MenSCs are highly proliferative mesenchymal-like stem cells with capability to differentiate to several different cell lineages.” Dr. Allickson is Vice President Laboratory Operations, Research & Development for Cryo-Cell International, Inc. Dr. Allickson’s expertise in Cell Therapy includes adult stem cell processing and banking along with research on adult stem cells for regenerative medicine.

About Cryo-Cell International, Inc.
Based in Oldsmar Florida, Cryo-Cell is the oldest and one of the largest family cord blood banks with over 240,000 clients worldwide. ISO 9001:2008 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company and trades under the symbol CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit http://www.cryo-cell.com.

About Cryo-Cell’s Menstrual Stem Cell Service
Cryo-Cell’s Menstrual Stem Cell service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit http://www.cryo-cell.com.

Forward-Looking Statement
Statements wherein the terms "believes", "intends", "projects", "anticipates", "expects", and similar expressions as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the success of the Company's global expansion initiatives and product diversification, the Company's actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company's future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company's business, the Company's ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company's Menstrual Stem Cell technology license agreements and Cord Blood Stem Cell Service license agreements and their ability to provide the Company with royalty fees, the ability of Cryology RTS to generate new revenues for the Company, and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.

# # #

Here is the original post:
Cryo-Cell International, Inc. Announces Material Transfer Agreement with Stanford University